vigabatrin

Summary

Summary: An analogue of GAMMA-AMINOBUTYRIC ACID. It is an irreversible inhibitor of 4-AMINOBUTYRATE TRANSAMINASE, the enzyme responsible for the catabolism of GAMMA-AMINOBUTYRIC ACID. (From Martindale The Extra Pharmacopoeia, 31st ed)

Top Publications

  1. Kjellström U, Andreasson S, Ponjavic V. Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication. Acta Ophthalmol. 2014;92:149-57 pubmed publisher
    ..retinal nerve fibre layer (RNFL) thickness with OCT in addition to the evaluation of retinal function measured by full-field electroretinography (ff-ERG) in patients with suspected vigabatrin (VGB)-attributed visual field defects.
  2. Conway M, Cubbidge R, Hosking S. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia. 2008;49:108-16 pubmed publisher
    The aims of this study were to develop an algorithm to accurately quantify Vigabatrin (VGB)-induced central visual field loss and to investigate the relationship between visual field loss and maximum daily dose, cumulative dose and ..
  3. Overstreet L, Westbrook G. Paradoxical reduction of synaptic inhibition by vigabatrin. J Neurophysiol. 2001;86:596-603 pubmed
    ..Gamma-vinyl GABA (vigabatrin, GVG) is an irreversible inhibitor of the GABA catabolic enzyme GABA transaminase, thus its anticonvulsant ..
  4. Lux A, Edwards S, Hancock E, Johnson A, Kennedy C, Newton R, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004;364:1773-8 pubmed
    ..b>Vigabatrin has been recorded to have a beneficial effect in this disorder...
  5. Luszczki J, Wojcik Cwikla J, Andres M, Czuczwar S. Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology. 2005;30:958-73 pubmed
    To characterize the anticonvulsant effects and types of interactions exerted by mixtures of vigabatrin (VGB) and conventional antiepileptic drugs (valproate (VPA), ethosuximide (ESM), phenobarbital (PB), and clonazepam (CZP)) in ..
  6. Buncic J, Westall C, Panton C, Munn J, MacKeen L, Logan W. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology. 2004;111:1935-42 pubmed
    To describe the clinical pattern of retinal atrophy in children caused by the anticonvulsant vigabatrin.
  7. Frisén L, Malmgren K. Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand. 2003;81:466-73 pubmed
    To report the discovery of a previously unknown form of optic atrophy associated with use of the anti-epileptic drug vigabatrin.
  8. Luszczki J, Czuczwar S. Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:529-38 pubmed
    To characterize the type of interactions between vigabatrin (VGB) and tiagabine (TGB) -- two newer antiepileptic drugs influencing GABA-ergic neurotransmitter system, the isobolographic analysis was used in two experimental models of ..
  9. Luszczki J, Ratnaraj N, Patsalos P, Czuczwar S. Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. Eur J Pharmacol. 2008;595:13-21 pubmed publisher
    The aim of this study was to characterize the pharmacodynamic, pharmacokinetic and adverse-effect profiles of vigabatrin and gabapentin...

More Information

Publications62

  1. Lee D, Schiffer W, Dewey S. Gamma-vinyl GABA (vigabatrin) blocks the expression of toluene-induced conditioned place preference (CPP). Synapse. 2004;54:183-5 pubmed
  2. McDonagh J, Stephen L, Dolan F, Parks S, Dutton G, Kelly K, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology. 2003;61:1690-4 pubmed
    To assess the wide-field multifocal electroretinogram (WF-mfERG) for assessment of retinal function in vigabatrin-treated patients.
  3. Storici P, De Biase D, Bossa F, Bruno S, Mozzarelli A, Peneff C, et al. Structures of gamma-aminobutyric acid (GABA) aminotransferase, a pyridoxal 5'-phosphate, and [2Fe-2S] cluster-containing enzyme, complexed with gamma-ethynyl-GABA and with the antiepilepsy drug vigabatrin. J Biol Chem. 2004;279:363-73 pubmed
    ..The antiepilepsy drug, gamma-vinyl-GABA (vigabatrin) has been investigated in the past by various biochemical methods and resulted in several proposals for its ..
  4. Lang A, De Angelis L. Experimental anxiety and antiepileptics: the effects of valproate and vigabatrin in the mirrored chamber test. Methods Find Exp Clin Pharmacol. 2003;25:265-71 pubmed
    The potential anxiolytic-like effects of valproate (VPA; 200, 300 and 400 mg/kg i.p.) and vigabatrin (GVG; 150, 300 and 450 mg/kg i.p.) were evaluated in an experimental model of anxiety in mice...
  5. Russo E, Citraro R, Scicchitano F, Urzino A, Marra R, Rispoli V, et al. Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity. Behav Brain Res. 2011;225:373-6 pubmed publisher
    To evaluate the effects of Vigabatrin (VGB) treatment, on both absence seizure and depressive-like behaviour development in the WAG/Rij rat model of absence seizures...
  6. Koul R, Chacko A, Ganesh A, Bulusu S, Al Riyami K. Vigabatrin associated retinal dysfunction in children with epilepsy. Arch Dis Child. 2001;85:469-73 pubmed
    Recent reports have established that eye changes occur in patients treated with vigabatrin.
  7. Hassan E, Belal F, al Deeb O, Khalil N. Spectrofluorimetric determination of vigabatrin and gabapentin in dosage forms and spiked plasma samples through derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole. J AOAC Int. 2001;84:1017-24 pubmed
    A highly sensitive and specific method is proposed for the determination of vigabatrin (I) and gabapentin (II) in their dosage forms and spiked human plasma...
  8. Humbertclaude V, Rivier F, Roubertie A, Echenne B, Bellet H, Vallat C, et al. Is hyperprolinemia type I actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance. J Child Neurol. 2001;16:622-3 pubmed
    ..Fluorescence in situ hybridization excluded a chromosome 22q11 deletion. Vigabatrin inhibits ornithine transaminase...
  9. Hilton E, Cubbidge R, Hosking S, Betts T, Comaish I. Patients treated with vigabatrin exhibit central visual function loss. Epilepsia. 2002;43:1351-9 pubmed
    To investigate visual function in the central 10 degrees in patients who have undergone vigabatrin (VGB) antiepileptic drug (AED) therapy with the aim of identifying a clinical regimen for assessing central visual function.
  10. Sills G, Patsalos P, Butler E, Forrest G, Ratnaraj N, Brodie M. Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina. Neurology. 2001;57:196-200 pubmed
    The antiepileptic drug (AED) vigabatrin (VGB) causes concentric visual field constriction...
  11. Werth R, Schädler G. Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin. Invest Ophthalmol Vis Sci. 2006;47:3028-35 pubmed
    In adult patients and in children of school age who have been treated with vigabatrin (VGB), persistent visual field defects have been reported as a side effect...
  12. Kinirons P, Cavalleri G, Singh R, Shahwan A, Acheson J, Wood N, et al. A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Res. 2006;70:144-52 pubmed
    Use of the antiepileptic drug (AED) vigabatrin is severely limited by irreversible visual field constriction, an adverse reaction to the drug reported in approximately 40% of patients...
  13. Wild J, Ahn H, Baulac M, Bursztyn J, Chiron C, Gandolfo E, et al. Vigabatrin and epilepsy: lessons learned. Epilepsia. 2007;48:1318-27 pubmed
    The risk factors for visual field loss attributable to vigabatrin (VAVFL) are equivocal. This multinational, prospective, observational study aimed to clarify the principal/major factors for VAVFL.
  14. Bouwman B, Suffczynski P, Midzyanovskaya I, Maris E, van den Broek P, Van Rijn C. The effects of vigabatrin on spike and wave discharges in WAG/Rij rats. Epilepsy Res. 2007;76:34-40 pubmed
    The effects of vigabatrin, which increases GABA concentrations by inhibiting GABA transaminase, on spike and wave discharges (SWDs) in the electroencephalogram of WAG/Rij rats were studied...
  15. Sobaniec W, Kułak W, Strzelecka J, Smigielska Kuzia J, Bockowski L. A comparative study of vigabatrin vs. carbamazepine in monotherapy of newly diagnosed partial seizures in children. Pharmacol Rep. 2005;57:646-53 pubmed
    ..b>Vigabatrin (VGB) is a relatively new second line antiepileptic drug and was first registered for use in Poland more than ..
  16. Coupland S, Zackon D, Leonard B, Ross T. Vigabatrin effect on inner retinal function. Ophthalmology. 2001;108:1493-6; discussion 1497-8 pubmed
    To determine the degree of electroretinal dysfunction in a group of patients taking Vigabatrin (VGB)...
  17. Camposano S, Major P, Halpern E, Thiele E. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia. 2008;49:1186-91 pubmed publisher
    To review the efficacy, cognitive outcome and safety profile in children treated with vigabatrin (VGB) for infantile spasms (IS) and partial epilepsies related to tuberous sclerosis complex (TSC) and other etiologies.
  18. Carpenter K, Timofeev I, Nortje J, Czosnyka M, Pickard J, Hutchinson P. A microdialysis study of oral vigabatrin administration in head injury patients: preliminary evaluation of multimodality monitoring. Acta Neurochir Suppl. 2012;114:271-6 pubmed publisher
    We assessed the feasibility of administering a neuroprotective drug, vigabatrin (VGB; gamma-vinyl-gamma-aminobutyric acid) with multimodality monitoring, including cerebral microdialysis, in severe head injury patients, to measure ..
  19. Nikolov R, Yakimova K. Effects of GABA-transaminase inhibitor Vigabatrin on thermoregulation in rats. Amino Acids. 2011;40:1441-5 pubmed publisher
    b>Vigabatrin is a GABA derivative (gamma-vinyl GABA) which inhibits irreversibly the enzyme activity of GABA transaminase and thus increased indirectly brain GABA concentrations...
  20. Kjellström U, Bruun A, Ghosh F, Andreasson S, Ponjavic V. Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication. Effect of vigabatrin in the rabbit eye. Graefes Arch Clin Exp Ophthalmol. 2009;247:1057-67 pubmed publisher
    To investigate, in a rabbit model, the effect of two different doses of vigabatrin (VGB) on retinal function and morphology.
  21. Chavooshi B, Saberi M, Pournaghash Tehrani S, Bakhtiarian A, Ahmadiani A, Haghparast A. Vigabatrin attenuates the development and expression of tolerance to morphine-induced antinociception in mice. Pharmacol Biochem Behav. 2009;93:155-9 pubmed publisher
    ..of the effect of anticonvulsant drugs on morphine antinociception, the present study investigated the effects of vigabatrin (VGB) on the development and expression of morphine tolerance in mice...
  22. Greiner H, Lynch E, Fordyce S, Agricola K, Tudor C, Franz D, et al. Vigabatrin for childhood partial-onset epilepsies. Pediatr Neurol. 2012;46:83-8 pubmed publisher
    To determine vigabatrin's effectiveness and the prevalence of symptomatic visual impairment (i.e...
  23. Muzykewicz D, Costello D, Halpern E, Thiele E. Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG. Epilepsia. 2009;50:290-6 pubmed publisher
  24. Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia. 2009;50:206-16 pubmed publisher
    The use of vigabatrin (VGB) as an antiepileptic drug (AED) has been limited by evidence showing that it causes vigabatrin-attributed visual field loss (VAVFL) in at least 20-40% of patients exposed at school age or later...
  25. Moseng L, Sæter M, Mørch Johnsen G, Hoff J, Gajda A, Brodtkorb E, et al. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity. Acta Ophthalmol. 2011;89:452-8 pubmed publisher
    To investigate whether persistent visual field defects among patients exposed once to the antiepileptic drug vigabatrin (VGB) were associated with peripapillary retinal nerve fibre layer thickness (RNFLT) attenuation.
  26. Bandini F, Castello E, Mazzella L, Mancardi G, Solaro C. Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis?. J Neurol Neurosurg Psychiatry. 2001;71:107-10 pubmed
    ..However, as gabapentin is not a selective GABAergic agent, vigabatrin, a "pure" GABAergic medication, and gabapentin, were compared in a single blind cross over trial in ..
  27. Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol. 2010;14:146-9 pubmed publisher
    ..There is a solid evidence of clinical efficacy of vigabatrin in interrupting infantile spasms associated with TSC...
  28. Parisi P, Bombardieri R, Curatolo P. Current role of vigabatrin in infantile spasms. Eur J Paediatr Neurol. 2007;11:331-6 pubmed
    b>Vigabatrin (VGB), a selective irreversible inhibitor of gamma-aminobutyric acid transaminase, has proved to be effective against cryptogenic and symptomatic infantile spasms (IS)...
  29. Lux A, Edwards S, Hancock E, Johnson A, Kennedy C, Newton R, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005;4:712-7 pubmed
    ..13 and 14 after randomisation is more common in infants allocated hormone treatments than in those allocated vigabatrin. We sought to assess whether early control of spasms is associated with improved developmental or epilepsy ..
  30. Lombardo S, Leanza G, Meli C, Lombardo M, Mazzone L, Vincenti I, et al. Maternal exposure to the antiepileptic drug vigabatrin affects postnatal development in the rat. Neurol Sci. 2005;26:89-94 pubmed
    The objective was to investigate, in the rat, the effects of maternal exposure to vigabatrin (VGB) on the postnatal motor-cognitive behaviour of the offspring. We used an experimental evaluator-blind, placebo-controlled study in the rat...
  31. Bouwman B, van Lier H, Nitert H, Drinkenburg W, Coenen A, van Rijn C. The relationship between hippocampal EEG theta activity and locomotor behaviour in freely moving rats: effects of vigabatrin. Brain Res Bull. 2005;64:505-9 pubmed
    ..theta activity and locomotor speed in both spontaneous and forced walking conditions was studied in rats after vigabatrin injection (500 mg/kg i.p.). Vigabatrin increased the percentage of time that rats spent being immobile...
  32. Ravindran J, Blumbergs P, Crompton J, Pietris G, Waddy H. Visual field loss associated with vigabatrin: pathological correlations. J Neurol Neurosurg Psychiatry. 2001;70:787-9 pubmed
    ..are reported in the anterior visual pathways of a 41 year old man with complex partial seizures treated with vigabatrin who developed bilateral visual field constriction...
  33. Spencer E, Harding G. Examining visual field defects in the paediatric population exposed to vigabatrin. Doc Ophthalmol. 2003;107:281-7 pubmed
    The antiepileptic drug, vigabatrin, has been linked to a specific pattern of visual field loss. The majority of studies have not included the paediatric population due to difficulties assessing visual field function...
  34. Aurich Barrera B, Wilton L, Brown D, Shakir S. Paediatric post-marketing pharmacovigilance: comparison of the adverse event profile of vigabatrin prescribed to children and adults. Pharmacoepidemiol Drug Saf. 2011;20:608-18 pubmed publisher
    ..However the methods may require modification to detect paediatric signals. The aim of this study was to compare the adverse event (AE) profile of children and adults taking vigabatrin, using modified signal detection methods (SDMs).
  35. Harding G, Spencer E, Wild J, Conway M, Bohn R. Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. Neurology. 2002;58:1261-5 pubmed
    To derive a visual-evoked potential (VEP) technique for identifying visual field defects in children with epilepsy treated with vigabatrin and unable to perform perimetry.
  36. Nabbout R, Melki I, Gerbaka B, Dulac O, Akatcherian C. Infantile spasms in Down syndrome: good response to a short course of vigabatrin. Epilepsia. 2001;42:1580-3 pubmed
    To evaluate the efficacy of vigabatrin (VGB) in the treatment of infantile spasms (ISs) associated with Down syndrome (DS) and to assess the feasibility of early discontinuation to reduce the possible retinal toxicity.
  37. Elterman R, Shields W, Mansfield K, Nakagawa J. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001;57:1416-21 pubmed
    Infantile spasms are a rare but devastating pediatric epilepsy that, outside the United States, is often treated with vigabatrin. The authors evaluated the efficacy and safety of vigabatrin in children with recent-onset infantile spasms.
  38. Heim M, Gidal B. Vigabatrin-associated retinal damage: potential biochemical mechanisms. Acta Neurol Scand. 2012;126:219-28 pubmed publisher
    b>Vigabatrin (VGB), an irreversible inhibitor of gamma-aminobutyric acid (GABA) transaminase, is approved as adjunct treatment of refractory partial seizures as well as infantile spasms...
  39. Bouwman B, van den Broek P, van Luijtelaar G, Van Rijn C. The effects of vigabatrin on type II spike wave discharges in rats. Neurosci Lett. 2003;338:177-80 pubmed
    The antiepileptic drug vigabatrin increases GABA concentrations by inhibiting GABA transaminase...
  40. Chahbouni A, Sinjewel A, den Burger J, Vos R, Wilhelm A, Veldkamp A, et al. Rapid quantification of gabapentin, pregabalin, and vigabatrin in human serum by ultraperformance liquid chromatography with mass-spectrometric detection. Ther Drug Monit. 2013;35:48-53 pubmed publisher
    Gabapentin (GBP), pregabalin (PRG), and vigabatrin (VIG) are used for the prevention and treatment of epileptic seizures. The developed method was applied to samples from subjects participating in a pharmacokinetic study of GBP.
  41. Wheless J, Carmant L, Bebin M, Conry J, Chiron C, Elterman R, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia. 2009;50:195-205 pubmed publisher
    b>Vigabatrin used to treat infantile spasms (IS) has been associated with transient magnetic resonance imaging (MRI) abnormalities...
  42. Frisén L. Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship. Acta Ophthalmol Scand. 2004;82:54-8 pubmed
    The utility of vigabatrin in the treatment of epilepsy is partially offset by its retinal toxicity. The relationship between dosage and damage is obscure. This may be due to perimetric shortcomings...
  43. Hemming K, Maguire M, Hutton J, Marson A. Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev. 2013;:CD007302 pubmed publisher
    ..The majority of these people have partial epilepsy. Vigabatrin is an antiepileptic drug licensed for use in the treatment of refractory epilepsy...
  44. Kröll Seger J, Kaminska A, Moutard M, de Saint Martin A, Guet A, Dulac O, et al. Severe relapse of epilepsy after vigabatrin withdrawal: for how long should we treat symptomatic infantile spasms?. Epilepsia. 2007;48:612-3 pubmed
  45. Wild J, Robson C, Jones A, Cunliffe I, Smith P. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci. 2006;47:917-24 pubmed
    To quantify retinal nerve fiber layer thickness (RNFLT) and macular thickness (MT) in patients exhibiting vigabatrin-attributed visual field loss (VAVFL) and to determine the efficacy of these measures as markers of the retinal damage ..
  46. Zwanzger P, Baghai T, Schuele C, Strohle A, Padberg F, Kathmann N, et al. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology. 2001;25:699-703 pubmed
    b>Vigabatrin increases gamma aminobutyric acid (GABA) levels by irreversible inhibition of the GABA-catabolizing enzyme GABA-transaminase (GABA-T). Preclinical studies suggest anxiolytic effects in vigabatrin treated rats...
  47. Clayton L, Dévilé M, Punte T, Kallis C, de Haan G, Sander J, et al. Retinal nerve fiber layer thickness in vigabatrin-exposed patients. Ann Neurol. 2011;69:845-54 pubmed publisher
    b>Vigabatrin-associated visual field loss (VAVFL) occurs in 25 to 50% of exposed patients and is routinely monitored using perimetry, which has inherent limitations...
  48. Olgun N, Erturk S, Atmaca S. Spectrofluorimetric and spectrophotometric methods for the determination of vigabatrin in tablets. J Pharm Biomed Anal. 2002;29:1-5 pubmed
    ..and selective spectrofluorimetric and spectrophotometric methods have been developed for the determination of vigabatrin in tablets. The methods are based on derivatization with 7-chloro-4-nitrobenzofurazan (NBD-Cl)...
  49. Pellock J, HRACHOVY R, Shinnar S, Baram T, Bettis D, Dlugos D, et al. Infantile spasms: a U.S. consensus report. Epilepsia. 2010;51:2175-89 pubmed publisher
    ..Differences of opinion among ISWG members occurred in areas where data were lacking; however, this article represents a consensus of the U.S. approach to the diagnostic evaluation and treatment of IS...
  50. Lawthom C, Smith P, Wild J. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity. Ophthalmology. 2009;116:565-71 pubmed publisher
    To investigate whether nasal peripapillary retinal nerve fiber layer (RNFL) attenuation is associated with visual field loss attributed to the anti-epileptic drug vigabatrin.
  51. Fueta Y, Kunugita N, Schwarz W. Antiepileptic action induced by a combination of vigabatrin and tiagabine. Neuroscience. 2005;132:335-45 pubmed
    b>Vigabatrin, an inhibitor of GABA breakdown by GABA transaminase and of GABA transporter isoform 1 (GAT1), and tiagabine, a highly specific inhibitor of GAT1, have successfully been applied in the treatment of epilepsy...
  52. Schmidt T, Rüther K, Jokiel B, Pfeiffer S, Tiel Wilck K, Schmitz B. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?. J Neurol. 2002;249:1066-71 pubmed
    To evaluate the reversibility of vigabatrin associated visual field constriction.
  53. Lindberger M, Luhr O, Johannessen S, Larsson S, Tomson T. Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. Ther Drug Monit. 2003;25:457-62 pubmed
    To explore possible concentration-effect relationships, gabapentin (GBP) and vigabatrin (VGB) serum concentrations were obtained from patients participating in an add-on dose-titration trial comparing GBP and VGB in partial epilepsy...